Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.41
- Piotroski Score 2.00
- Grade Buy
- Symbol (HOTH)
- Company Hoth Therapeutics, Inc.
- Price $0.83
- Changes Percentage (-0.1%)
- Change -$0
- Day Low $0.80
- Day High $0.84
- Year High $1.73
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.88
- Trailing P/E Ratio -0.58
- Forward P/E Ratio -0.58
- P/E Growth -0.58
- Net Income $-7,845,390
Income Statement
Quarterly
Annual
Latest News of HOTH
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
MPs urge government to regulate UK psychotherapists and counsellors
MPs advocate for statutory regulation of psychotherapists and counsellors in the UK to protect vulnerable individuals from harm. Current lack of regulation allows unqualified individuals to practice, ...
By The Guardian | 1 week ago -
Good psychotherapists will welcome statutory regulation | Letters
Philippa Smethurst advocates for statutory regulation to elevate the profession's credibility and safeguard the public from rogue practitioners. Sue Lieberman emphasizes the need for distinct regulati...
By The Guardian | 3 weeks ago -
Psychotherapists in England must be regulated, experts say, after abuse claims rise
Calls for regulating psychotherapists and counsellors in the UK have increased due to a rise in lawsuits for misconduct during therapy. Lack of statutory regulation allows unqualified individuals to p...
By The Guardian | 1 month ago
